BioSig Technologies entered into a Letter of Intent (LOI) to enter a proposed merger with Streamex Exchange Corp., a real-world asset tokenization firm, in an all-stock transaction.

Once the transaction is completed, Streamex co-founder and CEO Henry McPhie will lead the company as CEO and a member of the board of directors. Streamex co-founder and chairman Morgan Lekstrom will become the company’s chairman.

Current BioSig chairman and CEO Anthony Amato will stay on the board, with further board members to be added after the definitive agreement is signed.

After the merger, Streamex stockholders will own about 19.9% of the company’s outstanding common stock.

“This merger represents a transformative opportunity for both our company and our shareholders,” said Amato. “By joining forces with Streamex, we are unlocking significant growth potential while continuing to advance our existing business. This partnership will expand our market reach, enhance our capabilities, and create even greater opportunities for driving substantial returns. I am incredibly excited about the promising future ahead for our shareholders.”

BioSig is a company focused on deciphering the body’s electrical signals, beginning with heart rhythms. The company’s PURE EP platform delivers clarity in arrythmia identification and visualization, giving clinicians actionable insights. Last July, the company acquired assets of Neuro-Kinesis, which developed a catheter-based diagnostic system aims to address the limitations of EP mapping.

Streamex has developed a technology stack that includes primary issuance and decentralized exchange infrastructure for on-chain commodity markets. By leveraging blockchain technology, Streamex aims to enhance liquidity and efficiency in the commodity finance sector.